Copyright
©The Author(s) 2021.
World J Gastroenterol. May 14, 2021; 27(18): 2177-2192
Published online May 14, 2021. doi: 10.3748/wjg.v27.i18.2177
Published online May 14, 2021. doi: 10.3748/wjg.v27.i18.2177
Table 1 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy
| Variable | Total, n = 11938 | SVR, n = 11629 | Non-SVR, n = 309 | P value |
| Sex, n (%) | ||||
| Male | 5762 (48.3) | 5553 (47.8) | 209 (67.6) | < 0.001 |
| Female | 6176 (51.7) | 6076 (52.2) | 100 (32.4) | |
| Age | 52.24 (51.77-52.70) | 52.24 (51.77-52.71) | 52.16 (50.74-53.58) | 0.869 |
| BMI (kg/m2) | 26.47 (26.29-26.64) | 26.45 (26.26-26.62) | 27.20 (26.68-27.72) | < 0.001 |
| Fibrosis | ||||
| F0 | 277 (1.9) | 225 (99.1) | 2 (0.9) | |
| F1 | 4539 (38.8) | 4469 (98.5) | 70 (1.5) | |
| F2 | 2249 (19.2) | 2204 (98.0) | 45 (2.0) | < 0.001 |
| F3 | 1717 (14.7) | 1684 (98.1) | 33 (1.9) | |
| F4 | 2974 (25.4) | 2828 (95.1) | 146 (4.9) | |
| Liver stiffness (kPa) | 12.72 (12.45-12.99) | 12.53 (12.29-12.76) | 20.27 (14.78-25.76) | < 0.001 |
| Child Pugh, n (%) | ||||
| A | 11320 (96.9) | 11050 (97.1) | 270 (89.7) | |
| B | 346 (3.0) | 315 (2.8) | 31 (10.3) | < 0.001 |
| C | 13 (0.1) | 13 (0.1) | 0 (0.0) | |
| MELD score | 7.81 (7.76-7.85) | 7.79 (7.74-7.84) | 8.39 (8.11-8.67) | < 0.001 |
| Esophageal varices, n (%) | ||||
| Yes | 989 (10.5) | 922 (10.1) | 67 (27.1) | < 0.001 |
| No | 8413 (89.5) | 8233 (89.9) | 180 (72.9) | |
| Ascites at the start of the treatment, n (%) | ||||
| No | 11742 (98.8) | 11444 (98.9) | 298 (96.4) | |
| Moderate | 136 (1.2) | 125 (1.1) | 11 (3.6) | < 0.001 |
| Tense | 6 (0.0) | 6 (0.0) | 0 (0.0) | |
| Encephalopathy at the start of the treatment, n (%) | ||||
| No | 11808 (99.4) | 11507 (99.5) | 301 (97.8) | |
| Grade 1-2 | 67 (0.6) | 60 (0.5) | 7 (2.2) | 0.001 |
| Grade 3-4 | 1 (0.0) | 1 (0.0) | 0 (0.0) | |
| History of hepatocellular carcinoma, n (%) | ||||
| Yes | 179 (1.5) | 167 (1.5) | 12 (4.1) | < 0.001 |
| No | 11515 (98.5) | 11231 (98.5) | 284 (95.9) | |
| Extrahepatic manifestations, n (%) | ||||
| Yes | 948 (8.3) | 916 (8.2) | 32 (10.8) | 0.282 |
| No | 10513 (91.7) | 10248 (91.8) | 265 (89.2) | |
| HIV coinfection, n (%) | ||||
| Yes | 587 (5.0) | 564 (4.9) | 23 (7.6) | 0.098 |
| No | 11161 (95.0) | 10881 (95.1) | 280 (92.4) | |
| HBV coinfection, n (%) | ||||
| Yes | 1570 (13.5) | 1526 (13.4) | 44 (14.6) | 0.851 |
| No | 10098 (86.5) | 9840 (86.6) | 258 (85.4) | |
| HBsAg(+), n (%)) | 124 (8.0) | 122 (8.1) | 2 (4.5) | 0.543 |
| Reactivation of HBV infection, n (%) | ||||
| Yes | 11 (0.1) | 11 (0.1) | 0 (0.0) | 0.510 |
| No | 10707 (99.9) | 10435 (99.9) | 272 (100.0) | |
| History of liver transplantation, n (%) | ||||
| Yes | 146 (1.2) | 144 (1.3) | 2 (0.7) | 0.576 |
| No | 11555 (98.8) | 11253 (98.7) | 302 (99.3) | |
| Course of treatment, n (%) | ||||
| As planned | 11516 (97.1) | 11238 (97.3) | 278 (90.2) | |
| Terminated early | 86 (0.7) | 71 (0.6) | 15 (4.9) | < 0.001 |
| Modified | 257 (2.2) | 242 (2.1) | 15 (4.9) | |
| Ascites appearing while on treatment, n (%) | ||||
| Yes | 64 (0.5) | 57 (0.5) | 7 (2.3) | < 0.001 |
| No | 11773 (99.5) | 11473 (99.5) | 300 (97.7) | |
| Encephalopathy appearing while on treatment, n (%) | ||||
| Yes | 43 (0.4) | 35 (0.3) | 8 (2.6) | < 0.001 |
| No | 11773 (99.6) | 11474 (99.7) | 299 (97.4) | |
| Gastrointestinal bleeding while on treatment, n (%) | ||||
| Yes | 16 (0.1) | 14 (0.1) | 2 (0.7) | 0.044 |
| No | 11798 (99.9) | 11494 (99.9) | 304 (99.3) |
Table 2 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy-laboratory parameters
| Variable | Total, n = 11938 | SVR, n = 11629 | Non-SVR, n = 309 | P value |
| Albumin (g/dL) | 4.37 (4.2-4.45) | 4.38 (4.29-4.46) | 4.02 (3.76-4.28) | < 0.001 |
| Bilirubin (mg/dL) | 0.80 (0.79-0.81) | 0.79 (0.78-0.80) | 1.06 (0.98-1.15) | < 0.001 |
| INR | 1.10 (1.07-1.12) | 1.10 (1.07-1.12) | 1.11 (1.08-1.13) | < 0.001 |
| PLT (K/μL) | 191.47 (190.07-192.85) | 192.62 (191.22-194.02) | 147.63 (139.07-156.19) | < 0.001 |
| ALT (U/L) | 78.39 (77.19-79.59) | 77.92 (76.71-79.13) | 96.07 (87.16-104.98) | < 0.001 |
| Creatinine (mg/dL) | 0.92 (0.89-0.96) | 0.93 (0.89-0.96) | 0.81 (0.79-0.83) | 0.749 |
| eGFR, n (%) | ||||
| < 30 mL/min | 137 (29.2) | 137 (29.7) | 0 (0.0) | |
| > 60 mL/min | 160 (34.0) | 157 (34.0) | 3 (37.5) | 0.252 |
| 30-60 mL/min | 173 (36.8) | 168 (36.3) | 5 (62.5) | |
| Hemoglobin (g/dL) | 14.40 (14.37-14.43) | 14.40 (14.37-14.44) | 14.35 (14.15-14.55) | 0.812 |
| HCV genotype, n (%) | ||||
| 1A | 434 (3.6) | 426 (3.7) | 8 (2.6) | |
| 1B | 9327 (78.1) | 9147 (78.7) | 180 (58.3) | |
| 2 | 20 (0.2) | 20 (0.2) | 0 (0.0) | < 0.001 |
| 3 | 1328 (11.1) | 1221 (10.5) | 107 (34.6) | |
| 4 | 575 (4.8) | 565 (4.9) | 10 (3.2) | |
| 5 | 1 (0.0) | 1 (0.0) | 0 (0.0) | |
| 6 | 2 (0.0) | 2 (0.0) | 0 (0.0) | |
| HCV RNA (log10) | 6.37 (6.34-6.39) | 6.36 (6.34-6.39) | 6.39 (6.31-6.46) | 0.004 |
- Citation: Janczewska E, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. World J Gastroenterol 2021; 27(18): 2177-2192
- URL: https://www.wjgnet.com/1007-9327/full/v27/i18/2177.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i18.2177